Novozymes A/S Company Profile (OTCMKTS:NVZMY)

About Novozymes A/S (OTCMKTS:NVZMY)

Novozymes A/S logoNovozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America. It develops and distributes solutions within the market areas agriculture, bioenergy, food & beverages, household care, leather, pharmaceuticals, forest products, textile and wastewater solutions. Novozymes operates through a range of partnerships with companies, such as Adisseo, Beta Renewables, DONG Energy and Monsanto, and is a parent company of Novozymes Belgium BVBA, Novozymes BioAg Limited, Novozymes Canada Limited, Albumedix A/S and Organobalance GmbH, among others.

Industry, Sector and Symbol:
  • Sector: Basic Materials
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:NVZMY
  • CUSIP: N/A
  • Web: www.novozymes.com
Capitalization:
  • Market Cap: $13.06784 billion
  • Outstanding Shares: 295,200,000
Average Prices:
  • 50 Day Moving Avg: $51.63
  • 200 Day Moving Avg: $46.27
  • 52 Week Range: $31.57 - $52.99
P/E:
  • Trailing P/E Ratio: 31.549
  • Foreward P/E Ratio: 28.59
  • P/E Growth: 25.210
Sales & Book Value:
  • Annual Revenue: $2.32 billion
  • Price / Sales: 6.62
  • Book Value: $5.83 per share
  • Price / Book: 8.92
Dividend:
  • Annual Dividend: $0.37
  • Dividend Yield: 0.7%
Profitability:
  • EBITDA: $811.86 million
  • Net Margins: 21.31%
  • Return on Equity: 27.44%
  • Return on Assets: 16.59%
Debt:
  • Current Ratio: 1.49%
  • Quick Ratio: 0.87%
Misc:
  • Average Volume: 20,262 shs.
  • Beta: 1.07
 

Frequently Asked Questions for Novozymes A/S (OTCMKTS:NVZMY)

What is Novozymes A/S's stock symbol?

Novozymes A/S trades on the OTCMKTS under the ticker symbol "NVZMY."

How were Novozymes A/S's earnings last quarter?

Novozymes A/S (OTCMKTS:NVZMY) announced its earnings results on Thursday, August, 6th. The company reported $0.33 EPS for the quarter, missing the Zacks' consensus estimate of $0.35 by $0.02. Novozymes A/S had a return on equity of 27.44% and a net margin of 21.31%. View Novozymes A/S's Earnings History.

When will Novozymes A/S make its next earnings announcement?

Novozymes A/S is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Novozymes A/S.

Where is Novozymes A/S's stock going? Where will Novozymes A/S's stock price be in 2017?

3 brokers have issued 12-month price objectives for Novozymes A/S's shares. Their predictions range from $47.50 to $47.50. On average, they anticipate Novozymes A/S's stock price to reach $47.50 in the next year. View Analyst Ratings for Novozymes A/S.

Who are some of Novozymes A/S's key competitors?

Who are Novozymes A/S's key executives?

Novozymes A/S's management team includes the folowing people:

  • Joergen Buhl Rasmussen, Chairman of the Board
  • Peder Holk Nielsen, President, Chief Executive Officer
  • Agnete Raaschou-Nielsen, Vice Chairman of the Board
  • Thomas Videbaek, Chief Operating Officer; Executive Vice President, Research, Innovation & Supply
  • Andrew Fordyce, Executive Vice President, Food & Beverages
  • Anders Lund, Executive Vice President, Household Care & Technical
  • Tina Sejersgaard Fanoe, Executive Vice President, Agriculture & Bioenergy
  • Lena Bech Halskov, Director, Employee Representative
  • Lars Hall Green, Director
  • Anders Hentze Knudsen, Director, Employee Representative

How do I buy Novozymes A/S stock?

Shares of Novozymes A/S can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novozymes A/S's stock price today?

One share of Novozymes A/S stock can currently be purchased for approximately $52.03.


MarketBeat Community Rating for Novozymes A/S (OTCMKTS NVZMY)
Community Ranking:  1.2 out of 5 (star)
Outperform Votes:  26 (Vote Outperform)
Underperform Votes:  81 (Vote Underperform)
Total Votes:  107
MarketBeat's community ratings are surveys of what our community members think about Novozymes A/S and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Novozymes A/S (OTCMKTS:NVZMY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $47.50
Consensus Price Target History for Novozymes A/S (OTCMKTS:NVZMY)
Price Target History for Novozymes A/S (OTCMKTS:NVZMY)
Analysts' Ratings History for Novozymes A/S (OTCMKTS:NVZMY)
Show:
DateFirmActionRatingPrice TargetDetails
5/10/2017Jefferies Group LLCReiterated RatingHold$47.50View Rating Details
2/10/2017J P Morgan Chase & CoDowngradeOverweight -> NeutralView Rating Details
1/5/2017Sanford C. BernsteinUpgradeMkt Perform -> OutperformView Rating Details
9/27/2016Berenberg BankInitiated CoverageSellView Rating Details
1/20/2016Goldman Sachs Group, Inc. (The)UpgradeSell -> NeutralView Rating Details
(Data available from 10/20/2015 forward)

Earnings

Earnings History for Novozymes A/S (OTCMKTS:NVZMY)
Earnings by Quarter for Novozymes A/S (OTCMKTS:NVZMY)
Earnings History by Quarter for Novozymes A/S (OTCMKTS NVZMY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017N/AView Earnings Details
10/22/2015$0.36$0.36ViewN/AView Earnings Details
8/6/2015$0.35$0.33ViewN/AView Earnings Details
4/24/2015$0.33$0.33ViewN/AView Earnings Details
1/20/2015$0.23$0.30ViewN/AView Earnings Details
10/27/2014$0.35$0.34ViewN/AView Earnings Details
8/15/2014$0.38$0.34ViewN/AView Earnings Details
5/20/2014$0.33$0.40ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Novozymes A/S (OTCMKTS:NVZMY)
Current Year EPS Consensus Estimate: $1.66 EPS
Next Year EPS Consensus Estimate: $1.82 EPS

Dividends

Dividend History for Novozymes A/S (OTCMKTS:NVZMY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Novozymes A/S (OTCMKTS:NVZMY)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Novozymes A/S (OTCMKTS:NVZMY)
Latest Headlines for Novozymes A/S (OTCMKTS:NVZMY)
Source:
DateHeadline
americanbankingnews.com logoNovozymes A/S (NVZMY) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 18 at 6:24 AM
finance.yahoo.com logoNovozymes A/S :NVZMY-US: Earnings Analysis: Q2, 2017 By the Numbers : August 21, 2017
finance.yahoo.com - August 22 at 1:08 AM
finance.yahoo.com logoNovozymes shares fall as Q2 pressured by detergent makers, Monsanto alliance
finance.yahoo.com - August 11 at 7:07 AM
seekingalpha.com logoNovozymes A/S reports 1H results
seekingalpha.com - August 11 at 6:20 AM
americanbankingnews.com logoNovozymes A/S (NVZMY) to Release Earnings on Friday
www.americanbankingnews.com - August 4 at 7:12 AM
marketwatch.com logoAre microbes the next revolution coming to Big Ag?
www.marketwatch.com - January 28 at 5:20 AM
us.rd.yahoo.com logoNovozymes upgraded by JP Morgan
us.rd.yahoo.com - December 9 at 6:53 PM
seekingalpha.com logoKerry Group Plc - The Biggest Fish In The Highly Fragmented Ingredient Market - Seeking Alpha
seekingalpha.com - January 30 at 1:44 PM
marketwatch.com logoNovozymes profit up; sees moderate growth in 2016 - MarketWatch
www.marketwatch.com - January 19 at 12:34 PM
marketwatch.com logoNovozymes profit up; sees moderate growth in 2016
www.marketwatch.com - January 19 at 12:34 PM
thestreet.com logoEuropean Stocks Rise on Climb in German Investor Confidence
www.thestreet.com - January 20 at 6:24 AM

Social

Chart

Novozymes A/S (NVZMY) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.